Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606684 · ClinicalTrials.gov registry record · Phase 2
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 602
- Enrollment target
- 20
- Study locations
NCT00606684 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 602 participants, below the 1,036-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00606684, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 602 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
Conditions Studied
Interventions
- DRUG GW642444 6.25
- DRUG GW642444 3mcg
- DRUG GW642444 12.5mcg
- DRUG GW642444 25mcg
- DRUG GW642444 50mcg
Study Locations (20)
California
- GSK Investigational Site - Fullerton
- GSK Investigational Site - Lakewood
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Rancho Mirage
- GSK Investigational Site - Sepuldeva
- GSK Investigational Site - Upland
Florida
- GSK Investigational Site - Brandon
- GSK Investigational Site - DeLand
- GSK Investigational Site - Miami
- GSK Investigational Site - Tampa
Alabama
- GSK Investigational Site - Florence
- GSK Investigational Site - Jasper
- GSK Investigational Site - Montgomery
Indiana
- GSK Investigational Site - Carmel
- GSK Investigational Site - Elkhart
- GSK Investigational Site - New Albany
Louisiana
- GSK Investigational Site - Lafayette
- GSK Investigational Site - Sunset
Delaware
- GSK Investigational Site - Newark
Georgia
- GSK Investigational Site - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606684
The ClinicalTrials.gov registry entry for NCT00606684 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 602 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,036-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (42% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 5 interventions - of which GW642444 6.25 is the first listed.
NCT00606684 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00606684 about?
NCT00606684 is a clinical study titled "A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)". This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
What is the current status of trial NCT00606684?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 602 participants. The study started on 2008-02. Estimated completion is 2008-10.
What conditions does trial NCT00606684 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00606684?
The interventions under investigation include: GW642444 6.25 (DRUG), GW642444 3mcg (DRUG), GW642444 12.5mcg (DRUG), GW642444 25mcg (DRUG), GW642444 50mcg (DRUG).
Who is sponsoring clinical trial NCT00606684?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606684 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
-
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.